Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are assessing how well erdafitinib works to treat gliomas that keep growing after treatment. The people in this study have glioma with a normal IDH gene and a fusion of two other genes (FGFR-TACC).
The purpose of this study is to assess the safety and effectiveness of combining three drugs to treat people with an IDH-mutant glioma that came back after chemotherapy or surgery. The three medications are pembrolizumab, olaparib, and temozolomide.
The purpose of this study is to assess the safety and effectiveness of combining a "bivalent" vaccine with two agents that stimulate the immune system: a sugar called beta-glucan and a medication called GM-CSF. The treatment is designed to prevent the relapse of patients with high-risk neuroblastoma that is in complete remission. This bivalent vaccine works by stimulating an immune response against two different antigens, which are markers on the surface of a cell.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Cancer that has spread from a solid tumor to the membranes lining the brain and spinal cord (leptomeninges) is called "leptomeningeal metastasis." Cerebrospinal fluid (CSF) is located between the leptomeninges, in a place called the "intrathecal space." Cancer cells within the CSF rely on iron for growth and survival. Researchers think that the study drug, deferoxamine (DFO), may be an effective treatment for leptomeningeal metastases because it helps remove iron from the body (including the CSF).
The purpose of this study is to assess the safety and effectiveness of combining pembrolizumab immunotherapy with standard chemotherapy drugs and autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma that has come back or continued to grow despite one regimen of prior therapy. Pembrolizumab blocks PD-1, a protein cancer cells use to evade detection by the immune system, thereby enabling the immune system to find and kill cancer cells.
Teclistamab is given as an injection under the skin. The goal is to see if lower doses or stopping treatment will have the same benefit with fewer side effects.
Researchers are doing this study to see if the combination of epcoritamab, zanubrutinib, and rituximab works well against lymphoma. The people in this study have follicular lymphoma that has come back or keeps growing after treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are comparing different treatments for non-muscle invasive bladder cancer (NMIBC). The people in this study have NMIBC that keeps growing after treatment with an immunotherapy called Bacillus Calmette-Guerin (BCG). They do not want surgery to remove the bladder (radical cystectomy).
